Focused On-demand Library for BTB/POZ domain-containing protein KCTD17

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8N5Z5

UPID:

KCD17_HUMAN

Alternative names:

Alternative UPACC:

Q8N5Z5; B0QYA9; B0QYB0; O95517

Background:

BTB/POZ domain-containing protein KCTD17 plays a pivotal role in ciliogenesis by acting as a substrate-adapter for CUL3-RING ubiquitin ligase complexes, facilitating the ubiquitination and proteasomal degradation of TCHP, a negative regulator of ciliogenesis. Additionally, it may influence endoplasmic reticulum calcium ion homeostasis, highlighting its multifunctional nature.

Therapeutic significance:

Linked to Dystonia 26, myoclonic, a disorder characterized by involuntary muscle contractions and abnormal postures, KCTD17's involvement suggests potential therapeutic targets. Understanding the role of BTB/POZ domain-containing protein KCTD17 could open doors to potential therapeutic strategies.